A. Patel

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

Byoung Chul Cho, Delvys Rodríguez‐Abreu, Maen Hussein et al. · The Lancet Oncology · 2022 · 424 citations · Full text

Medicine, Oncology, Pharmacology +14

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

Delvys Rodríguez‐Abreu, Melissa L. Johnson, Maen Hussein et al. · Journal of Clinical Oncology · 2020 · 242 citations

Medicine, Oncology, Pharmacology +17

Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting

Natasha Khrystolubova, Monica Shieh, A. Patel et al. · Journal of Oncology Pharmacy Practice · 2019 · 29 citations · Full text

Pharmacy, Oncology, Pharmacy Practice +17

LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC

B.C. Cho, Delvys Rodríguez‐Abreu, Maen Hussein et al. · Annals of Oncology · 2021 · 24 citations

Medicine, Oncology, Pharmacology +12

Clinical Experience With Prophylactic Fondaparinux in Critically Ill Patients With Moderate to Severe Renal Impairment or Renal Failure Requiring Renal Replacement Therapy

Jessica Cope, Jennifer Bushwitz, Guohua An et al. · Annals of Pharmacotherapy · 2014 · 14 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacotherapy +17